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Fetal/neonatal brain injury is an important cause of neurological disability. Hypoxia-ischemia and excitotoxicity are considered
important insults, and, in spite of their acute nature, brain injury develops over a protracted time period during the primary,
secondary, and tertiary phases. The concept that most of the injury develops with a delay after the insult makes it possible to
provide eﬀective neuroprotective treatment after the insult. Indeed, hypothermia applied within 6 hours after birth in neonatal
encephalopathy reduces neurological disability in clinical trials. In order to develop the next generation of treatment, we need to
know more about the pathophysiological mechanism during the secondary and tertiary phases of injury. We review some of the
critical molecular events related to mitochondrial dysfunction and apoptosis during the secondary phase and report some recent
evidence that intervention may be feasible also days-weeks after the insult.
1.Introduction
Brain injury occurring during the perinatal period is a com-
mon cause of life-long neurological disability. The etiol-
ogy is complex and multifactorial, but hypoxia-ischemia
(HI), infection/inﬂammation, and excitotoxicity are consid-
ered important causes or precipitating insults of prevent-
able/treatable forms of perinatal brain injury. Genetic back-
ground, maturational age, sex, and degree of brain devel-
opment of particular regions aﬀect vulnerability and the
mechanisms of brain injury [1, 2]. Furthermore, antecedents
like infection/inﬂammation, intrauterine growth restriction,
or preexposure to hypoxia can modulate brain vulnerabili-
ty [3–5]. Brain injury evolves over time, and diﬀerent mech-
anisms are critical during the primary, secondary, and ter-
tiary phases. Indeed, recent experimental data suggests that
interventions can be eﬀective if administered hours, days, or
even weeks after the primary insult [6, 7].
The aim of the present paper is to describe the critical
mechanisms of brain injury during the diﬀerent stages after
an acute insult with particular emphasis on mitochondrial
impairment, apoptotic events and the tertiary phase of
injury.
2.Secondary BrainInjury
Cerebral HI that is suﬃciently severe to cause depletion of
tissue energy reserves (primary insult) is often followed by
transientbutcompleterestorationofglucoseutilization,ATP
and phosphocreatine upon reoxygenation [8–10]. Thereafter
a secondary decrease of high energy phosphates occurs in
experimental studies that parallel a decrease in tissue glucose
metabolism and development of cell injury [8–10]. In a
similar way, infants with neonatal encephalopathy exhibit
characteristic abnormalities in cerebral energy metabolism,2 Neurology Research International
which is frequently normal soon after birth, but shows a pro-
gressive decline in [PCr]/[Pi] some hours later [11]. Infants
displaying this phenomenon develop neurodevelopmental
impairment or die, and there is a close relationship between
the magnitude of the late decline in [PCr]/[Pi] and the
severity of long-term neurodevelopmental impairment [12].
These ﬁndings suggest that most of the injury after HI
evolveswithdelayedonsetafter ratherthanduringtheinsult.
There are many examples of successful posttreatment after
HI in animals suggesting a therapeutic window following
HI prior to the secondary phase of tissue impairment [13].
Hypothermia following HI reduces secondary energy failure
and brain injury in newborns with neonatal encephalopathy
[14]. However, the mechanisms involved in secondary brain
injury are largely unknown and such knowledge is critical
for development of future therapies for preterm infants or
to be combined with hypothermia in severely asphyxiated
infants at term, hopefully, to further reduce serious disability
in children and adults.
3. MitochondrialFunctionalImpairment
Mitochondria are small membrane-enclosed organelles, re-
markably mobile and plastic, constantly changing their
shape and undergoing fusion and ﬁssion [15]. Many factors
can challenge mitochondrial balance and good functioning:
DNA mutations, increase of intracellular calcium, reactive
oxygen species, inﬂammation, decrease in trophic factors,
and mitochondrial dysfunction plays a crucial role in brain
injury [16]. Because of the heterogeneity of mitochondria
existing in the brain, to understand variations in mitochon-
dria functioning and consequent selective vulnerability to
injury, the organelle must be placed within the context of
its cellular, functional, developmental, and neuroanatomical
environment [17, 18]. The location of mitochondria in the
cell varies between cell types, but they are most often lo-
calized near sites of high ATP utilization as their major role
is to produce and supply energy, ATP, to the cells through the
enzymecomplexesformingtherespiratorychain.Mitochon-
drial function is critically important during development
and throughout life in metabolic tasks like cellular prolifer-
ation, regulation of the cellular red-ox state, apoptosis, and
excitotoxic injury.
Interest is growing in mitochondrial diseases or mito-
chondria-related injury where the respiratory chain/oxida-
tive phosphorylation system starts to malfunction. Mito-
chondrial diseases are principally due to mutations in either
nuclear or mitochondrial DNA, provoking impairment of
transcription, translation and assembly of the enzyme com-
plexes, leading to the malformation and/or malfunction of
the mitochondria [19, 20]. Impairment of the respiratory
chain is associated with ageing, neurodegenerative disorders
[21], and mitochondrial diseases [19]. During ageing, inef-
ﬁciency of the respiratory chain has been linked to the
decreased activity of AMP-activated protein kinase (AMPK)
leading to decreased mitochondrial biogenesis and function
[22,23].Inneurodegenerativedisorders,likeParkinson’sand
ALS, an increase of oxidative stress is shown to be a crucial
initiator aﬀecting respiratory chains, leading ultimately to
cell death [21, 24]. As well, recent discoveries of mutation
associated with hereditary form of those diseases render the
story even more complex [25].
Very little is known of what happens to the respiratory
chain in injuries like stroke or during perinatal brain dam-
age. After neonatal hypoxia-ischemia (HI), there is a sig-
niﬁcant energy failure in the brain, followed by a recovery
period before a second energy failure [2, 26–29]. Those pri-
mary and secondary energy failures are associated with the
primary and secondary injury [30]. Currently, most of˜the
research on perinatal brain damage is focusing on the sec-
ondary insult leading to cell death and tissue injury [31].
However, what is happening during the primary energy fail-
ure, what is happening during the short recovery, and what
mechanisms lead to the second energy failure and injury
remain unknown.
4. The Role of AMPK inMitochondrial
EnergyCrisis
Challenges to mitochondrial biogenesis and integrity are
most likely to happen quite early in the cascade of events
leading ultimately to injury. Before being involved in the
apoptotic process after HI ([31–33] and see paragraph
below) and considering the role of mitochondria as a major
ATP supplier, it is most likely that mitochondria are involved
from the ﬁrst steps of the injury process after the insult.
For instance, our group recently identiﬁed a peak of AMPK
activity as early as 20min after an HI insult in the brain of
neonatal mice (Rousset et al., unpublished data). AMPK is
well known as the energy sensor of the cell and is activated
when there is an imbalance in the AMP:ATP ratio such as
that which occurs in heat shock, anoxia, and so forth [34].
Once activated, AMPK will inhibit energy-consuming path-
ways (fatty acid/cholesterol synthesis) and promote energy-
producing pathways (glycolysis, e.g., or through PGC-1α
increasing mitochondria biogenesis, [35, 36]) in an attempt
to restore energy balance which is critical to cell survival.
AMPK is activated through two upstream kinases: LKB1 and
CaMKKβ [37–41]. The latter is activated by a surge of intra-
cellular calcium within the cell [40], which happens during
excitotoxicity, a well-described feature of HI injury mech-
anism [42]. Furthermore, AMPK has recently been shown
to mediate apoptosis through expression of the proapoptotic
protein Bim after an excitotoxic challenge in vitro [43].
Hypothetically, as a ﬁrststep, the calciumsurgeprovoked
by excitotoxicity and ROS signalling [44, 45] could not only
activate CaMKKβ and then AMPK but could also simultane-
ously challenge the mitochondrial respiratory chain leading
to an imbalance in the AMP/ATP ratio, reinforcing AMPK
activation through the second upstream kinase LKB1. The
activation of downstream pathways of AMPK to restore
energy balance, could logically explain the return to basal
level of ATP in the brain after the primary energy failure.
Subsequently, events in the mechanistic cascade responsible
for HI injury, like inﬂammation [32], could theoretically
once again impede mitochondrial function, causing theNeurology Research International 3
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Figure 1: A potential role for AMPK in neonatal brain injury.
AMPK is activated in response to stresses which change either
intracellular calcium levels (e.g., excitotoxicity) or deplete intra-
cellular ATP concentrations (e.g., inﬂammation, reactive oxygen
species). Although AMPK works to return energy levels to baseline,
prolonged activation results in upregulation of the proapoptotic
protein, Bim.
secondary energy failure (Figure 1). This, cumulating with
an overactivation of AMPK, which has been reported to
exacerbate injury after stroke [46, 47], and still ongoing dele-
terious consequences from previous events, could provoke
in the most vulnerable cells a ﬁnal mitochondrial challenge,
leading to its membrane permeabilisation and ultimately cell
death through apoptotic pathways.
5. MitochondrialFusion and Fission
Mitochondria constantly fuse and divide, and the mecha-
nisms governing this aspect of mitochondrial behaviour are
currently the focus of many investigations. This property
to fuse and divide appears to be crucial for a number of
functions, the maintenance of organelle ﬁdelity, mediating
DNA or protein quality control, and, ﬁnally, it may be
an important feature during apoptosis [48]. Mitochondrial
fusion proteins attenuate apoptosis by inhibiting the release
of proapoptotic agents like cytochrome c, while mitochon-
drial ﬁssion protein DRP-1 promotes apoptosis through Bax,
leading to mitochondrial outer membrane permeabilization
and cell death [49]. However, it is of note that fusion and
ﬁssion have not yet been investigated in the immature brain,
but this is surely something of great interest to push forward.
6. IntrinsicPathway of Apoptosis and
SecondaryBrainInjury
Apoptosis (programmed cell death) is essential for the nor-
mal development of tissues and is especially key in neuronal
development. The balance between cell survival and cell
death is therefore required to be highly regulated; as such it is
unsurprising that aberrant activation of apoptotic pathways
occurs in a number of pathological conditions including
stroke and a variety of neurodegenerative diseases [50].
Cellular apoptosis can be achieved through two routes,
the extrinsic pathway (discussed later) activated in response
to extracellular signals such as Fas and TNFα and mediated
by death receptors [51] and the intrinsic pathway activated
in response to DNA damage or cellular stress. Although each
pathway has unique members, both mechanisms converge
downstream at the level of the mitochondrion, where if the
insultissevereenough,thereiscatastrophicpermeabilisation
fromwhichthecellcannotrecover.Mitochondrialpermeabi-
lisation results in the release of mitochondrial apoptogenic
factors into the cytosol including apoptosis-inducing factor
(AIF), endonuclease g (endo G) cytochrome c (cyt c), and
Smac/Diablo.Theseproteinshaveanumberofpro-apoptotic
functions; cyt c interacts with Apaf-1 to form an active
apoptosome,providingaplatformforprocaspase-9cleavage;
Smac/Diablo interacts with inhibitors of apoptosis (IAP) re-
ducing their negative inﬂuence on the activity of caspases
[50]. In contrast with cyt c and Smac/Diablo, AIF and endo
G operate through a caspase-independent pathway. Both
are translocated to the nucleus from the mitochondria in
response to death—inducing stimuli where they induce frag-
mentation of nuclear DNA [52, 53].
7.TheRoleofCaspasesinNeonatalBrainInjury
Caspases play a key role in apoptosis and inﬂammation. Cas-
pases can be divided into three groups: initiator caspases
(caspase-2, -8, -9, -10), eﬀector caspases (caspase-3, -6, -7),
and inﬂammatory caspases (caspase-1, -4, -5, -11, -12).
Whereas eﬀector caspases are activated by the initiator cas-
pases,initiator caspasesareactivatedbydiﬀerent, more com-
plex mechanisms [54].
In the extrinsic pathway, binding ligands to death recep-
tor leads to recruitment of adaptor protein, which recruits
caspase-8, forming DISC (death-inducing signaling com-
plex) leading to dimerization and activation of caspase-8.
Caspase-8 then cleaves and activates eﬀector caspases. In the
intrinsic pathway, after cyt c is released from mitochondria
into cytosol, it interacts with Apaf-1. This complex binds to
procaspase-9 in the presence of dATP/ATP and forms the
apoptosome which cleaves and activates initiator caspase,
caspase-9 which, in turn, activates eﬀector caspases (in par-
ticular, caspase-3) by cleaving between their large and small
subunits [55]. Activated eﬀector caspases cleave cellular sub-
strates,suchasPARP(poly(ADP-ribose)polymerase),lamin,
fodrin, ROCK1 (Rho-associated kinase 1),and ICAD (inhib-
itor of CAD), leading to DNA fragmentation, cell shrinkage,
and membrane blebbing [56–58]. Among the eﬀector cas-
pases, caspase-3 cleaves a broad range of substrates and the
main eﬀector caspase in the brain.
During brain development, a large number of neurons
are eliminated by apoptosis to optimize neural networks.
The activation of caspase-3 appears in the execution of
neuronal apoptosis in the brain during development and
after acute injury like HI. The extent of caspase-3 activation4 Neurology Research International
following brain injury is greater in immature brain than
adults [59, 60]. Caspases are important for apoptosis in
developing brain. Nevertheless, there is the implication that
caspase-independent death pathways may also inﬂuence
nervous system development and may provide an alternative
mechanism for regulating neuronal death.
The initial report characterising caspase-3-deﬁcient mice
showed defects of apoptosis in the nervous system; these
mice die during embryonic development or in the perinatal
period, in a manner similar to the phenotype of caspase-
9 and Apaf1-deﬁcient mice. Subsequently, it was reported
that caspase-3 deﬁciency on C57/BL/6J background pro-
duced only minor neuropathological changes and caspase-
3-deﬁcient C57/BL/6J mice survived into adulthood [61].
Moreover, neonatal HI brain injury in caspase-3-deﬁcient
mice is worse compared with the previous model [62]. In
rats subjected to neonatal HI, there is a peak of caspase-3
activity observed 24h after the insult which remains elevated
for a signiﬁcant number of days [63]. These data suggest
that the apoptotic pathway is likely to be strain dependent
and caspase-independent death pathways may also inﬂuence
nervous system development and may provide an alternative
mechanism for regulating neuronal death. Recent studies
have also revealed the nonapoptotic function of caspases. In
particular, caspase-3 is suggested to function in neurogenesis
and synaptic activity [64].
Caspase-6 is an eﬀector caspase, and, in apoptotic path-
ways, lamin, a structural protein of nuclear envelope, is
thought to be the only substrate cleaved exclusively by cas-
pase-6. In other pathways, caspase-6 is also known to cleave
cytoskeletalandstructuralproteins,suchasthemicrotubule-
associated protein tau and amyloid precursor protein (APP),
and caspase-6 is detected in neurodegenerative diseases, such
as Alzheimer’s disease and Huntington’s disease. Recently,
Nikolaev and colleagues identiﬁed APP/death receptor-6
(DR6)/caspase-6 pathway as the mechanism speciﬁc for axo-
nal pruning and degeneration by trophic factor withdrawal
in developing neurons [65]. As a result, the involvement of
caspase-6 in axonal degeneration has come under a high
degree of scrutiny [66, 67]. Recently, it was demonstrated
that caspase-6 gene deﬁciency conferred protection in a
m o u s em o d e lo fa d u l ts t r o k ew i t har e d u c t i o no fa x o n a l
degeneration and improvement of functional outcome [66].
We have recently found that caspase-6 is activated (cleaved)
also in neurites in the immature brain after HI (Miyakuni
et al., personal communication), but its pathophysiological
importance remains unknown.
8. ARoleforMitochondrialPermeabilisationin
Secondary BrainInjuryinNeonatalHI
Mitochondrial permeabilisation (MP) therefore represents
the “point of no return” in the life cycle of the cell. Two
forms of permeability have been identiﬁed. Mitochondrial
outer membrane permeability (MOMP) is the result of
Bcl-2 family members such as Bax relocating from the
cytosol to the mitochondria. Once there, Bax interacts with
another Bcl-2 family member Bak to form pores in the
outermembraneenablingproteinslocatedbetweentheinner
and outer membranes to leak into the cytosol [68]. In
contrast, a permeability transition pore (PTP) is formed
at points where both the inner and outer leaﬂets of the
mitochondrion are at their closest points. In contrast with
MOMP,theinnermitochondrialmembraneispermeabilised
resulting in leakage of solutes, depolarisation due to proton
gradient equilibration, and generation of reaction oxygen
species.ATPproductionceasesandthemitochondrionswells
ultimately disrupting the outer membrane. PTP-mediated
cell death is predominantly necrotic (through calcium im-
balance and bioenergetic failure), although in extreme cases,
if suﬃcient ATP is present, apoptosis can occur through
activation of caspases [69]. Induction of the PTP is enhanced
by cyclophilin D, a mitochondrial matrix protein which
has previously been implicated in adult ischaemic injury
[70]. However, our recent studies demonstrated that Bax-
mediated MOMP rather than cyclophilin-D-mediated PTP
is critical in mouse models of neonatal HI [71]. Indeed,
previous work from our group and others suggests that, in
neonatal brain, Bax-dependent mitochondrial outer mem-
brane permeabilisation is implicated (Figure 2).
9. Involvement of Bax and Other Proapoptotic
Bcl-2 FamilyMembers inNeonatal HI
A study examining Bax-deﬁcient mice found that these
animals were protected in immature brain injury paradigms
[72]. Furthermore, studies which ablate the eﬀects of Bax-
mediated mitochondrial membrane permeabilisation (e.g.,
knockout models of Bim and Bad [73], Tat-Bcl-xL-mediated
neuroprotection[74],Bcl-xLtransgenicmice[75])allexhibit
reduced brain injury after neonatal HI. Pharmacologically,
intracerebroventricular injection of Bax inhibitory peptide
prior to induction of HI in a neonatal mouse model con-
ferred neuroprotection in both grey and white matters [76].
Finally, both caspase-dependent and AIF pathways are acti-
vated to a much greater extent in the immature brain com-
pared with the adult brain [60]. Taken together, these data
suggest that Bax-dependent mitochondrial permeabilisation
is a critical event in delayed brain injury because it leads to
bothactivationofcaspase-dependentandcaspase-independ-
ent cell death and mitochondrial functional impairment.
10.Upstream Regulators ofProapoptotic
Bcl-2 FamilyMembers
10.1. p53. It is a tumour suppressor that triggers apop-
tosis via multiple pathways including cell cycle arrest and
the regulation of autophagy through transactivating pro-
apoptoticandrepressingantiapoptoticgenes[77].Itishighly
conserved and regulates cell death resulting from a wide
variety of both physiological and pathological stimuli [78].
p53 also has transcription-independent, cytoplasmic actions
at the mitochondrial level and can promote Bax-dependent
mitochondrial permeabilisation [79]. In unstressed neurons,
p53expressionisgenerallylow,limitedbyitsassociationwith
its negative regulator MDM2 which functions as a ubiquitinNeurology Research International 5
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Figure 2: The development of secondary brain injury. Energy depletion culminating in Bax-dependent mitochondrial permeabilisation
represents an irreversible commitment to cell death in neonatal brain injury.
ligase, targeting polyubiquitinated p53 for degradation [80].
Cellular stress displaces p53 from MDM2, and subsequently
p53 expression is stabilised through substantial posttransla-
tional modiﬁcation [77] .T h ec l a s s i c a lr o l ef o rp 5 3i sa sa n
activator of transcription, and, on stabilisation, it accumu-
lates in the nucleus where it upregulates the transcription
of proapoptotic genes such as PUMA, BAX, and Noxa
[81]. More recently a cytosolic, transcription-independent
role was described in which activated p53 accumulates in
the cytosol where it is sequestered by the antiapoptotic
Bcl2 proteins for example, Bcl-xL [79]. However, increased
PUMA expression mediated by nuclear p53 displaces Bcl-
xL allowing p53 to activate Bax, promoting its oligomerisa-
tion, mitochondrial outer membrane permeabilisation, and
inducing apoptosis [79, 82].
A previous study found that p53 was upregulated and
accumulated in the nucleus and mitochondria in an in vivo
rat model of neonatal HI. In consequence, there was an
upregulation of apoptotic pathways leading to activation of
caspase-3. The authors identiﬁed a pathway involving NFκB
upstream of p53 and were able to decrease p53 accumulation
(thus increasing neuronal survival), in response to neonatal
HIbytreatingwiththeNFκBinhibitorNBDpeptide[83,84].
Subsequently, this has translated into improved long-term
function in behavioural tests [85]. More recently, the same
group conﬁrmed the importance of p53 activation in neona-
tal HI by use of a small molecule inhibitor of p53, piﬁthrin-
μ. Injection of this peptide into mice which have previously
been subjected to an HI paradigm results in a high degree of
protection in both white and grey matters which translates
into long-lasting behavioural beneﬁts compared with sham-
injected animals [86]. As piﬁthrin-μ is widely believed to
inhibit the mitochondrial but not nuclear functions of p53
[87], this strengthens the case for critical involvement of a
p53-Bax pathway in neonatal HI.
10.2. C-Jun N-Terminal Kinases (JNKs). These are members
of the mitogen-activated protein kinase (MAPK) family and,
as such, are activated in response to stress. There are three
mammalian jnk genes and 10 expressed isoforms as the
result of alternative splicing; however, it is JNK3 that is pre-
dominantly active in the brain [88]. In a mouse model in
which JNK3 expression is ablated (JNK3 KO), both adult
and neonatal animals were partially protected against HI
insult, and, in newborn animals, levels of c-jun were reduced
compared with wild-type animals [89, 90]. This correlates
with an earlier study suggesting that expression of c-Jun and
its subsequent phosphorylation was increased on ischaemic
injury [91]. JNK3 is hypothesised to act upstream of the
proapoptotic Bcl-2 family as JNK3-mediated increases in
Bim and PUMA expression were absent in the JNK3 KO ani-
mal [90]. In addition, activation of caspase-3 was also de-
creased suggesting that activation of JNK3 in response to
hypoxic-ischaemic insult results in caspase-dependent apop-
tosis.
10.3. Caspase-2. It is a member of the initiator subgroup of
caspases and is developmentally regulated [92]. Activation
of caspase-2 is dependent on its dimerisation and subse-
quent cleavage which is facilitated through interaction with
PIDD (p53-induced death domain-containing protein) and
RAIDD (RIP-associated ICH-1/CED3 homologous protein
with a death domain) [93–95]. Once activated, caspase-2
promotes Bid cleavage resulting in Bax translocation and
release of cyt c [96]. In a very recent study, caspase-2
null newborn mice were found to be partially protected
in both excitotoxic and HI paradigms [97]i nc o n t r a s t
with the adult caspase knockout mouse model [98]. As the
study also showed high expression of caspase-2 in neonatal
mice and rats which decreased postnatally, it is probably
unsurprising that there are age-dependent diﬀerences in
caspase-2function.Interestingly,agroupIIcaspaseinhibitor,
TRP601, has recently been developed which targets caspase-
2 and caspase-3 functions. Neonatal animals subjected to
excitotoxicity, arterial stroke, or HI insult were signiﬁcantly
protected against white and grey matter loss [99].6 Neurology Research International
11.DeathReceptorsandthe Extrinsic
Pathway of Apoptosis
During inﬂammation such as that which has been reported
in perinatal brain injury [32], activation of mast cells [100]
and microglia will produce reactive oxygen species, release
excitatory amino acid agonists, proinﬂammatory cytokines
(e.g., IL-1γ, IL-18, TNF-α), chemokines [101, 102], and
tumour necrosis factors (e.g., TNF-α,T N F - β, FasL, TRAIL,
TWEAK) [101, 103–105] that will contribute to cell death
most often characterized by a mixed apoptotic-necrotic phe-
notype [59, 106].
FromthetimeTNFwasclonedandcharacterizedin1984
[107], roughly 20 ligand-receptor pairings are now included
in the TNF superfamily. These TNF and TNF-receptor-like
moleculesaresimilarinstructuretoTNFandarefunctioning
as trimers (both ligands and receptors). The receptors are
largely membrane-bound signalling molecules with excep-
tion of some soluble decoy receptors (e.g., Osteoprotegerin).
Theligandsinsteadcanbeeithermembraneorsolubleforms
and both forms can have physiological activity. Because of
the similarity of their structure, multiple ligands are able
to bind and induce signalling through one receptor, or a
single ligand is able to bind multiple receptors. Some of
the receptors contain the so-called death domain in their
intracellular domain (e.g., TNF-R1, DR4, DR5, Fas) and are
able to trigger apoptosis when activated from the binding of
the corresponding ligand (e.g., TNF- α, TRAIL, FasL). This
extrinsic pathway of apoptosis continues with the activation
of a death-inducing signalling complex (DISC) adjacent to
the death domain of the receptor. Activated DISC catalyzes
the proteolytic cleavage and transactivation of procaspase-8
[108]. Activated caspase-8 either directly activates caspase-
3 or mediates cleavage of Bcl-2 interacting domain (Bid) to
truncated Bid (tBid), which integrates diﬀerent death path-
ways at the mitochondria ([109]; Figure 3). tBid translocates
to mitochondria where it interacts with other proapoptotic
proteins and triggers the release of apoptogenic factors
like cyt c and apoptosis-inducing factor (AIF) from the
mitochondria. Apoptosis then proceeds in the same way
as for the intrinsic pathway with caspase-dependent and
caspase-independent cell death.
12.Necroptotic CellDeath
Activation of death receptors in the presence of broad-spec-
trum caspase inhibitors induces a newly described cell death
process called necroptosis. Necroptotic cell death initiated by
TNF-α,Fas,orTRAILismediatedbyformationofacomplex
of two kinases, RIP1 and RIP3. This complex promotes
mitochondrialreactiveoxygenspecies(ROS)productionand
eventual collapse of cellular energy production [110].
13. Involvement of Death Receptors in
Neonatal Brain Injury
TNF-α activity is mediated through activation of two recep-
t o r s :l o w ,a ﬃnity TNFR1 (p55) and the high-aﬃnity TNFR2
(p75) [111], found on both neuronal [112, 113] and glial
cell populations [114]. Although the extracellular domains
of both receptors have a high degree of homology, their in-
tracellular domains diﬀer signiﬁcantly [115]. This leads to
complex signal transduction pathways that can be triggered
and may result in activation of the antagonistic functions of
these two receptors [111, 116]. When activated, the intracel-
lular part of TNFR1 containing the death domain triggers
apoptosis[117],whereasTNFR2lacksthatdomain—itsacti-
vation triggers neuroprotection through activation of NFκB
[118]. There are several pieces of evidence that suggest the
involvementoftheTNFpathwayinthedevelopmentofwhite
matter damage (WMD). Children who develop cerebral
palsy show increased blood levels of TNF-α [119], and TNF
receptor1iscriticalforLPS-mediatedsensitizationtooxygen
glucose deprivation in vitro [120]. Moreover, deletion of the
TNFgeneclusterabolishes LPS-mediatedsensitization ofthe
neonatal brain to HI insult [121]. TNF-α treatment appears
to be toxic for the oligodendroprecursor (OPC) cell [122]
and potentiates the IFN-γ toxicity on those cells in vitro
[123]. TNF-α has also been shown to stimulate astrocyte
[124] and microglial [114] activation and proliferation.
TNF-α-mediated cell destruction may be mediated directly,
via activation of its TNFR and subsequent cell death sig-
nalling pathways, or indirectly by enhancing glutamate exci-
totoxicity [125]. TNF is also implicated in brain neuropro-
tection. It is shown that neuronal damage by focal cerebral
ischemia and excitotoxic insults are enhanced in TNFR KO
mice [126]. The neuroprotective role for TNF in cerebral
ischemia is mainly attributed to TNFR2 activity [127].
FasL is able to bind with Fas death receptor triggering
apoptosis and with Decoy receptor 3 (DcR3) [128]. Fas
death receptor is one of the most extensively studied of this
group of receptors. Lack of functional Fas receptor is neu-
roprotective in adult models of HI [129, 130]. HI also acti-
vates Fas death receptor signalling in the neonatal brain
especially in areas where apoptosis is a prominent fea-
ture [131–133]. Although the Fas/FasL system is primarily
linked to apoptosis, Fas activation can also induce caspase-
independent cell death [134], initiate cell necrosis [135], or
induce proliferation and diﬀerentiation signals [136]. It is
shown that Fas expression in primary OPC is higher than
in mature oligodendrocytes [123], implying higher suscepti-
bility to FasL at earlier developmental stages. Fas expression
can be upregulated in OPCs exposed to an inﬂammatory
stimulus [123] which may imply that in an inﬂammatory
environment these cells would have increased vulnerability
to Fas-induced apoptosis.
In humans, four membrane-bound and one soluble re-
ceptor for TRAIL have been identiﬁed. Of these, two contain
cytoplasmic death domain (DR4 and DR5) and have the
capacity to induce apoptotic cell death [137, 138], whereas
DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4) lack functional
d e a t hd o m a i n sa n dt h u sa r ec o n s i d e r e dt oa c ta sd e c o y
receptors [139, 140]. Osteoprotegerin (OPG) is a secreted
T N Fr e c e p t o rf a m i l ym e m b e rt h a tb e s i d e sr e c e p t o ra c t i v a t o r
of nuclear factor kappa-B ligand (RANKL) can bind TRAIL
as well [141, 142]. In mice, two membrane decoy receptors
mDcTRAILR1 and mDcTRAILR2 have been reported [143],Neurology Research International 7
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Figure 3: The extrinsic pathway of apoptosis. Inﬂammatory cells secrete death receptor ligands which bind to receptors on neurons,
oligodendroglial and other receptor-expressing cells, recruiting the death-inducing signalling complex (DISC) and triggering both apoptotic
and necroptotic pathways.
one soluble OPG [142], and only one death-mediating
TRAIL receptor which has the highest homology with the
human TRAIL receptor DR5 [144].
Only one receptor for TWEAK has been identiﬁed so
far in both humans and rodents, ﬁbroblast growth factor-
inducible 14 (Fn14) [145]. Binding of TWEAK to this recep-
tor can trigger proliferation, diﬀerentiation, migration, and
cell death [146]. The Fn14 cytoplasmic tail does not contain
a canonical death domain, and TWEAK binding to Fn14
can induce multiple cell death pathways in diﬀerent cellular
contexts [147, 148].
Although many studies have been conducted in the can-
cer- or inﬂammation-related systems, the role of TRAIL and
TWEAKinthedevelopmentofWMDafterHIisstillunclear.
The studies that implicate TRAIL and TWEAK signalling in
the pathogenesis of ischemic cerebral damage are performed
in adult models of stroke or multiple sclerosis and concern
mainly neurons [105, 148–150]. To date very few studies
relate these pathways to OPC death [61]. However, intrac-
erebroventricular injection of soluble DR5 receptor [150]o r
Fn14 [105] is able to reduce signiﬁcantly the infarct volume
after HI in adult rodent models, strongly implicating TRAIL
and TWEAK signalling in neuronal cell death after HI.
14. Tertiary BrainInjury
Tertiary brain injury will be deﬁned as that occurring follow-
ing the commonly deﬁned events of primary and secondary
cell death. As outlined previously, perinatal brain injury
is predominantly caused by inﬂammation/infection and
hypoxic-ischemic events that cause metabolic dysfunction
and cell death. Even after secondary cell death has subsided,
eﬀects on the brain persist including sensitisation to inﬂam-
mation or injury, increased seizure susceptibility, impaired
oligodendrocyte maturation and myelination, and persistent
inﬂammation and gliosis [151–156]. More speculatively,
perinatal inﬂammation is suggested to play a critical role in
the pathogenesis of autism and schizophrenia [157–159].
When considering treatments for tertiary brain injuries,
we could distinguish between strategies aiming at extending
the window of therapeutic intervention from the acute
phase to the subacute phase and strategies targeting more8 Neurology Research International
long-term events such as chronic inﬂammation or postle-
sional plasticity.
15.Extendingthe Window
One key issue for protecting the perinatal brain is the
available window for intervention in the processes leading
to cell death. From a clinical point of view, the longer this
window,betterthechancetoimplementviableinterventions.
For example, hypothermia has to be initiated within the ﬁrst
6 hours of life to be protective in term infants with neonatal
encephalopathy [160]. Such a short window does not allow
applying this treatment to all neonates who might beneﬁt
from it. As a strategy to enhance the eﬃcacy of hypothermia,
some groups have been trying to extend the window of
intervention of hypothermia by giving ﬁrst an antiepileptic
drug prior to delayed hypothermia. Using the classical Rice-
Vannucci P7 rat model, Liu and colleagues have shown
that a combination of low-dose topiramate administered
15 minutes after the HI insult and 3-hour hypothermia
initiated 3 hours after the insult was neuroprotective while
topiramate alone or hypothermia alone had no signiﬁcant
eﬀect [161]. More recently, the same group showed that
early administration of Phenobarbital also enhanced the
eﬃcacy of delayed hypothermia [162]. It remains to be seen
if drugs used successfully in parallel with hypothermia, such
as melatonin and xenon, might also be able to extend the
therapeutic window of this treatment [163, 164].
An alternative strategy would be to use early but short-
term hypothermia to enhance the window of opportunity
for a protective drug. This strategy could allow reducing
the duration of hypothermia. Accordingly, it was shown that
fructose-1,6-biphosphate (FBP) was neuroprotective against
neonatal excitotoxic cortical damage [165]. However, the
drug had to be given within the ﬁrst 8 hours to be neuropro-
tective. Interestingly, a moderate but transient (4 hours)
coolingimmediately aftertheinsult extendedthetherapeutic
window for FBP, as FBP administered 24h after the excitoto-
xicinsultwasstillsigniﬁcantlyneuroprotectiveinthesepups.
16. Targeting the Long-LastingInﬂammation
A recent and intriguing study performed in preterm infants
with cerebral palsy [155] suggests that, at least in some pa-
tients with perinatal brain damage, there could be a long-
lasting inﬂammation as measured by increased TNF-α levels
in the plasma and the supernatants of peripheral blood
mononuclear cells after lipopolysaccharide stimulation. This
long-lasting altered inﬂammatory response could have dele-
terious eﬀects on the progression of disease and/or on
the clinical symptoms. If such a pathophysiological event
was conﬁrmed, recognizing and blocking such a persistent
inﬂammation could be of therapeutic value.
Additional studies are necessary to conﬁrm these new
hypotheses and to determine whether or not there is a long-
lasting CNS inﬂammatory process. Techniques such as PET
with markers of microglia or MRI using ferromagnetic par-
ticles taken up by activated microglia could be instrumental
in this perspective. Indeed, a study using this approach has
revealed that for many years after traumatic brain injury in
human adults microglia remain activated [166]. Although
thesestudieshavenotyetbeenreproducedinchildren/young
adults following perinatal injury, a similar activation might
be ongoing and therefore a target for reducing tertiary phase
injury.
1 7 .T arg etin gE p ig e n eticM ark s
The term epigenetics refers to the enzymatic (e.g., acetyla-
tion, methylation) and nonenzymatic mechanisms (micro-
RNA) by which gene expression/cell phenotype is modiﬁed
without altering the sequence of genomic DNA. Inﬂamma-
tion, growth restriction, and maternal stress are known to
altertheepigenome[167–170],andalthoughintheperinatal
period these eﬀects alone may not lead to classic brain
injury, they may cause long-lasting cognitive, motor, and/or
behavioural impairments [151, 167, 171].
The underlying mechanisms by which modifying the
epigenome could have lasting eﬀects includes myelin deﬁcit
linked to blockade of oligodendrocyte maturation, impaired
neuronal migration, increased neuronal cell death, impaired
axonal growth, or altered synaptogenesis [172–175]. Of par-
ticular interest, microRNAs with suggested roles in regenera-
tion and repair are upregulated from 3 days after MCAO
[176], and microRNAs are capable of enhancing the beneﬁ-
cialmicroglialM2phenotype[177].IfmicroRNAsdoindeed
represent an endogenous repair and immunomodulatory
mechanism,theymaybeanovelstrategytotreatbraininjury
in the tertiary phase.
Drugs speciﬁcally targeting acetylation have shown great
eﬃcacy in treating acute-phase adult cerebral injuries (see,
[178]), and evidence is mounting to suggest eﬃcacy in neo-
natal models ([179]; Fleiss and Mallard, unpublished). We
do not yet know if modulating the epigenome after the
secondary phase will have any eﬃcacy after inﬂammation
or HI. However, adult changes in behaviour stemming from
perinatalmaternalstressandlinked toincreasedmethylation
can be abolished in adulthood by increasing acetylation
[180]. This raises hope for the future design of innovative
treatments that could be implemented way beyond the
perinatal insult.
18. Promoting PositivePost-LesionalBrain
Regeneration with M2 Microglia
Activated microglia have been shown to be detrimental for
the production of hippocampal neurons, but microglia and
macrophages can also be beneﬁcial and support neurogene-
sis, progenitor proliferation, survival, migration, and diﬀer-
entiation in other brain regions. Recent studies suggest that
the phenotypic expression of macrophages can vary depend-
ing on the situation and pro-inﬂammatory macrophages
(M1) can undergo transition into an anti-inﬂammatory-
reparative (M2) phenotype. More recently, three activation
states of microglia in CNS have been proposed: classical acti-Neurology Research International 9
vation(tissuedefence,pro-inﬂammatory),alternativeactiva-
tion (repair, anti-inﬂammatory, ﬁbrosis, extracellular matrix
reconstruction), and acquired deactivation (immunosup-
pression, phagocytosis of apoptotic cells [181, 182]).
Strategies aiming at activating microglia when it has
reached the M2 phase could be beneﬁcial for facilitating
repair and plasticity. Of note, the early phases of microglial
activation (M1 type of activation) have typically been
describedasdeleteriousforthebrain.Morerecently,prevent-
ing early microglial activation has been shown to be detri-
mental in focal ischaemia [183, 184]. This suggests caution
in timing of any intervention to modify microglial activity.
Alternatively, or in parallel, strategies aiming at acceler-
ating the M1-M2 switch could also be of major interest. At
this point, it is not known if modulation of the activation
state of microglia/macrophages can be used for development
of novel therapeutic strategies in the developing brain,
but a recent report suggests that M2 (alternative activa-
tion/acquired deactivation) macrophage cell therapy indeed
can provide protective eﬀects in an animal model of multiple
sclerosis [185].
19. Promoting PositivePost-LesionalBrain
Regeneration with Exogenous Stem Cells
The development of an adequate protocol for stem cell cul-
turing and application has envisaged the use of these cells
for the reparation of perinatal cerebral lesions. Some studies
have shown a positive eﬀect of neural or mesenchymal stem
cell therapy on the lesion extent and/or cognitive or motor
outcome following perinatal brain lesions [7, 186]. Interest-
ingly, in some of these studies, positive eﬀects were observed
when stem cells were injected several days (up to 10 days)
aftertheinsult.Furthermore,inanadultMCAOmodel,stem
cells given even 30d post-insult improved neurobehavioural
scoringassessed50dlatersuggestingeﬃcacymaybepossible
even in the tertiary phase of perinatal brain injury [187].
The therapeutic potential of neural stem cells in acute
neonatal brain injuries has been evaluated in a rodent excito-
toxic model [186]. Early (4-hour) and late (72-hour) neural
stemcellsimplantationsigniﬁcantlyreducedbrainlesionsize
inthisneonatalmodel.Theimplantedcells,modiﬁedinvitro
prior to transplantation toward the oligodendrocytic lineage,
were capable of migrating toward the lesion site even when
implanted contralaterally to the lesion. At the lesion site,
the neural stem cellsunderwent transient diﬀerentiation into
neurons and oligodendrocytes but not astrocytes, suggesting
thatfatespeciﬁcationwasachievedbythecultureconditions.
Pre-implantation cell fate determination may oﬀer some
ability to speciﬁcally target white matter injury, such as
predominates in the injured immature brain [188–191]. In
parallel with the reduction in lesion size, the injured mice
displayed a persistent and marked improvement in temporal
and spatial memory at 3 and 6 weeks of age compared to
littermates given intracerebroventricular injections of saline
or ﬁbroblasts.
Similarly, it was recently shown that two administra-
tions of bone marrow-derived mesenchymal stem cells to
neonatal mice 3 and 10 days after unilateral right carotid
artery occlusion on P9 produced a 46% improvement in
sensorimotor function as observed in the cylinder rearing
test and a 60% decrease in neuronal loss, compared with
vehicle-treated animals [7]. Moreover, cellular proliferation
and diﬀerentiation of the proliferated cells into cells express-
ing neuronal, oligodendroglial and astrocyte markers was
observed. Interestingly, remodeling of the corticospinal tract
correlated with sensorimotor improvement.
It is not clear yet whether the stem cells themselves or
factors secreted by stem cells mediate the positive eﬀect.
Increased neurotrophin production with eventual loss of
injected cells is linked to improvements [186], while in
some studies cells become functionally integrated [192].
The ethical problem associated with the use of human
stem cells is less evident in mesenchymal stem cells or
stem cells derived from cord blood. Such cells permit an
autologous transplant and do not entail the problem of
immunetoleranceofthetransplantedcells.Aclinicalstudyis
currently being performed using stem cells in children with
neonatal encephalopathy at the Duke University [193].
A further intriguing alternative to treatment with stem
cells is to stimulate the production of endogenous neuronal
stem cells. It has already been shown that stem cells
accumulate in the subventricular zone following an acute
brain lesion. These results open a new perspective: the
stimulation of this stem cell population to support the
physiological reparation processes of a lesion. A variant of
this strategy would be to redirect new cell production from
astroglia to oligodendrocytes and neurons [194]. Critically,
stem cell therapies and stimulating endogenous proliferation
bears the theoretical risk of cancer induction [193].
20. Promoting PositivePost-LesionalBrain
Regeneration with Pharmacological Agents
Fostering positive post-lesional plasticity appears a very pro-
mising strategy for delayed interventions aiming at improv-
ing long-term neurological and cognitive function. However,
there is still limited knowledge about the cellular and molec-
ular mechanisms underlying post-lesional brain plasticity.
Diﬀerent growth factors, such as brain-derived neuro-
trophic factor (BDNF), nerve growth factor (NGF), insulin-
like growth factor-1 (IGF-1), erythropoietin (EPO), or vas-
oactive intestinal peptide (VIP), have been shown to reduce
delayedneuronaldeathinvariousanimalmodelsofperinatal
brain damage [195–199]. As for hypothermia, the window
forintervention,whentested,wasratherrestrictedtotheﬁrst
hours after the insult. However, beyond their potential capa-
bilitytopreventneuronalcelldeath,growthfactorsappearas
good candidates to target mechanisms involved in plasticity
such as proliferation of neuronal precursors, axonal growth
and sprouting, or synaptogenesis and synaptic stabilization.
Accordingly, BDNF and VIP have been shown to pro-
mote axonal sprouting following excitotoxic injury of the
periventricular white matter in newborn mice [198, 199].
Although growth factors like BDNF are big molecules un-
likely to cross easily through the intact blood-brain barrier,10 Neurology Research International
ampakines, allosteric positive modulators of glutamatergic
AMPA receptors, are small and diﬀusible molecules able to
induce BDNF production in the brain when administered
systemically. Interestingly, ampakines have been shown to
mimicBDNFeﬀectsonaxonalsproutinginthemousemodel
of excitotoxic white matter injury [200].
Similarly, melatonin was shown to promote plasticity
using the same model of neonatal excitotoxic white matter
damage [42]. Although melatonin did not prevent the ini-
tial appearance of white matter damage, it promoted repair
of secondary lesion with axonal regrowth and/or sprouting.
Recent data have shown that the window for intervention
is at least 24 hours after the insult (Gressens P, personal
communication). Behavioural studies support the hypothe-
sis that melatonin-induced white matter histological repair
is accompanied by improved learning capabilities. Neuro-
protective properties of melatonin have been conﬁrmed in
several animal models of perinatal brain damage, including
fetal sheep [201]. Melatonin is a safe compound, including
newborns[202],anditcrossestheblood-brainbarrieraswell
as the placenta. Based on these data, a clinical trial testing
the neuroprotective eﬀects of melatonin has been initiated in
preterm infants at high risk of developing brain damage and
neurological handicap [203].
Although this study needs to be replicated, an intriguing
clinical study has recently shown that EPO, when given
on an average of 24 hours after birth, had very signiﬁcant
neuroprotective eﬀects in human term infants with neonatal
encephalopathy [204]. Evidently, the precise mechanism for
this neuroprotection is unknown, but the timing of inter-
vention argues on favour of an eﬀect of EPO on post-lesional
plasticity although a direct eﬀect on delayed neuronal cell
death cannot be excluded.
Authors Contribution
C. Thornton and C. I. Rousset contributed equally to this
work. P. Gressens and H. Hagberg shared senior authorship.
Acknowledgments
This work was supported by Medical Research Council stra-
tegic award (MRC, UK, P19381 to H. Hagberg), Medical
Research Council (VR, Sweden, 2006-3396 to H. Hagberg),
ALF-LUA (Sweden, ALFGBG2863 to H. Hagberg), Wellcome
Trust (Programme Grant WT094823MA to H. Hagberg, P.
Gressens), Inserm, Universit´ e Paris 7, APHP (Contrat d’In-
terface to P. Gressens), Fondation Leducq (Pierre Gressens,
H. Hagberg), Fondation Grace de Monaco (P. Gressens), and
Fondation Roger de Spoelberch (P. Gressens).
References
[1] M.V.JohnstonandH.Hagberg,“Sexandthepathogenesisof
cerebral palsy,” Developmental Medicine and Child Neurology,
vol. 49, no. 1, pp. 74–78, 2007.
[2] S. J. Vannucci and H. Hagberg, “Hypoxia-ischemia in the
immature brain,” Journal of Experimental Biology, vol. 207,
no. 18, pp. 3149–3154, 2004.
[ 3 ]M .A .D o m m e r g u e s ,J .P a t k a i ,J .C .R e n a u l d ,P .E v r a r d ,a n d
P. Gressens, “Proinﬂammatory cytokines and interleukin-9
exacerbateexcitotoxiclesionsofthenewbornmurineneopal-
lium,” Annals of Neurology, vol. 47, no. 1, pp. 54–63, 2000.
[4] S. Eklind, C. Mallard, A. L. Leverin et al., “Bacterial endotox-
in sensitizes the immature brain to hypoxic-ischaemic inju-
ry,”EuropeanJournalofNeuroscience,vol.13,no.6,pp.1101–
1106, 2001.
[5] J. M. Gidday, J. C. Fitzgibbons, A. R. Shah, and T. S. Park,
“Neuroprotection from ischemic brain injury by hypoxic
preconditioning in the neonatal rat,” Neuroscience Letters,
vol. 168, no. 1-2, pp. 221–224, 1994.
[6] F. F. Gonzalez and D. M. Ferriero, “Neuroprotection in the
Newborn Infant,” Clinics in Perinatology, vol. 36, no. 4, pp.
859–880, 2009.
[ 7 ]C .T .J .v a nV e l t h o v e n ,A .K a v e l a a r s ,F .v a nB e l ,a n dC .J .
Heijnen, “Repeated mesenchymal stem cell treatment after
neonatal hypoxia-ischemia has distinct eﬀects on forma-
tion and maturation of new neurons and oligodendrocytes
leading to restoration of damage, corticospinal motor tract
activity, and sensorimotor function,” Journal of Neuroscience,
vol. 30, no. 28, pp. 9603–9611, 2010.
[8] R. M. Blumberg, E. B. Cady, J. S. Wigglesworth, J. E. McKen-
zie, and A. D. Edwards, “Relation between delayed impair-
ment of cerebral energy metabolism and infarction following
transient focal hypoxia-ischaemia in the developing brain,”
Experimental Brain Research, vol. 113, no. 1, pp. 130–137,
1997.
[9] E. Gilland, E. Bona, and H. Hagberg, “Temporal changes of
regionalglucoseuse,bloodﬂow,andmicrotubule-associated
protein 2 immunostaining after hypoxia-ischemia in the im-
mature rat brain,” Journal of Cerebral Blood Flow and Meta-
bolism, vol. 18, no. 2, pp. 222–228, 1998.
[10] A. Lorek, Y. Takei, E. B. Cady et al., “Delayed (“secondary”)
cerebral energy failure after acute hypoxia-ischemia in the
newborn piglet: continuous 48-hour studies by phosphorus
magneticresonancespectroscopy,”PediatricResearch,vol.36,
no. 6, pp. 699–706, 1994.
[11] D. Azzopardi, J. S. Wyatt, E. B. Cady et al., “Prognosis of
newborn infantswithhypoxic-ischemic braininjuryassessed
by phosphorus magnetic resonance spectroscopy,” Pediatric
Research, vol. 25, no. 5, pp. 445–451, 1989.
[12] S. C. Roth, J. Baudin, E. Cady et al., “Relation of deranged
neonatal cerebral oxidative metabolism with neurodevelop-
mental outcome and head circumference at 4 years,” Devel-
opmental Medicine and Child Neurology, vol. 39, no. 11, pp.
718–725, 1997.
[13] M. Thoresen, J. Penrice, A. Lorek et al., “Mild hypothermia
after severe transient hypoxia-ischemia ameliorates delayed
cerebral energy failure in the newborn piglet,” Pediatric Re-
search, vol. 37, no. 5, pp. 667–670, 1995.
[ 1 4 ]A .D .E d w a r d s ,P .B r o c k l e h u r s t ,A .J .G u n ne ta l . ,“ N e u r o l o g -
ical outcomes at 18 months of age after moderate hypother-
mia for perinatal hypoxic ischaemic encephalopathy: synthe-
sisandmeta-analysisoftrialdata,”BMJ,vol.340,articlec363,
2010.
[15] J.Bereiter-HahnandM.Voth,“Dynamicsofmitochondriain
living cells: shape changes, dislocations, fusion, and ﬁssion of
mitochondria,” Microscopy Research and Technique, vol. 27,
no. 3, pp. 198–219, 1994.
[16] S. DiMauro and E.A.Schon, “Mitochondrial disordersin the
nervous system,” Annual Review of Neuroscience, vol. 31, pp.
91–123, 2008.Neurology Research International 11
[17] J.M.Dubinsky,“Heterogeneity ofnervoussystemmitochon-
dria: location, location, location!,” Experimental Neurology,
vol. 218, no. 2, pp. 293–307, 2009.
[18] G. L. Rintoul and I. J. Reynolds, “Mitochondrial traﬃcking
and morphology in neuronal injury,” Biochimica et Biophys-
ica Acta, vol. 1802, no. 1, pp. 143–150, 2010.
[19] R. Kucharczyk, M. Zick, M. Bietenhader et al., “Mitochon-
drial ATP synthase disorders: molecular mechanisms and the
questforcurativetherapeuticapproaches,”BiochimicaetBio-
physica Acta, vol. 1793, no. 1, pp. 186–199, 2009.
[20] E. A. Schon and E. Area-Gomez, “Is Alzheimer’s disease a
disorder of mitochondria-associated membranes?” Journal of
Alzheimer’s Disease, vol. 20, no. 2, pp. S281–S292, 2010.
[21] M. Baron, A. P. Kudin, and W. S. Kunz, “Mitochondrial dys-
function in neurodegenerative disorders,” Biochemical Socie-
ty Transactions, vol. 35, no. 5, pp. 1228–1231, 2007.
[22] F. R. Jornayvaz and G. I. Shulman, “Regulation of mitochon-
drial biogenesis,” Essays in Biochemistry, vol. 47, pp. 69–84,
2010.
[23] R. M. Reznick, H. Zong, J. Li et al., “Aging-associated
reductions in AMP-activated protein kinase activity and
mitochondrial biogenesis,” Cell Metabolism,v o l .5 ,n o .2 ,p p .
151–156, 2007.
[24] A.G.Barsukova,D.Bourdette,andM.Forte,“Mitochondrial
calcium and its regulation in neurodegeneration induced by
oxidative stress,” European Journal of Neuroscience, vol. 34,
no. 3, pp. 437–447, 2011.
[25] E.SchonandS.Przedborski,“Mitochondria:TheNext(Neu-
rode)Generation,” Neuron, vol. 70, no. 6, pp. 1033–1053,
2011.
[26] D. Azzopardi, J. S. Wyatt, P. A. Hamilton et al., “Phosphorus
metabolites and intracellular pH in the brains of normal
and small for gestational age infants investigated by magnetic
resonancespectroscopy,”PediatricResearch,vol.25,no.5,pp.
440–444, 1989.
[27] F. E. O’Brien, O. Iwata, J. S. Thornton et al., “Delayed whole-
body cooling to 33 or 35◦C and the development of im-
paired energy generation consequential to transient cerebral
hypoxia-ischemia in the newborn piglet,” Pediatrics, vol. 117,
no. 5, pp. 1549–1559, 2006.
[28] S. J. Vannucci, F. Maher, E. Koehler, and I. A. Simpson,
“Altered expression of GLUT-1 and GLUT-3 glucose trans-
porters in neurohypophysis of water-deprived or diabetic
rats,” American Journal of Physiology, vol. 267, no. 4, part 1,
pp. E605–E611, 1994.
[29] J. S. Wyatt, A. D. Edwards, D. Azzopardi, and E. O. R.
Reynolds, “Magnetic resonance and near infrared spectro-
scopy for investigation of perinatal hypoxic-ischaemic brain
injury,” Archives of Disease in Childhood,v o l .6 4 ,n o .7 ,p p .
953–963, 1989.
[30] U.Dirnagl,C.Iadecola,andM.A.Moskowitz,“Pathobiology
of ischaemic stroke: an integrated view,” Trends in Neurosci-
ences, vol. 22, no. 9, pp. 391–397, 1999.
[31] H. Hagberg, C. Mallard, C. I. Rousset Catherine, and X.
Wang, “Apoptotic mechanisms in the immature Brain: in-
volvement of mitochondria,” Journal of Child Neurology, vol.
24, no. 9, pp. 1141–1146, 2009.
[32] H. Hagberg, C. Rousset, K. Savman, and C. Mallard, “Hypo-
xic-ischemic brain injury: apoptotic and inﬂammatory
mechanisms,” in Mechanisms of Hypoxic Brain Injury in the
Newborn and Potential Strategies for Neuroprotection, pp. 35–
55, Transworld Research Network, Trivandrum, India, 2007.
[33] H. Hagberg, “Mitochondrial impairment in the developing
brain after hypoxia-ischemia,” Journal of Bioenergetics and
Biomembranes, vol. 36, no. 4, pp. 369–373, 2004.
[34] D. Carling, “AMP-activated protein kinase: balancing the
scales,” Biochimie, vol. 87, no. 1, pp. 87–91, 2005.
[35] S. J¨ aer, C. Handschin, J. St-Pierre, and B. M. Spiegelman,
“AMP-activated protein kinase (AMPK) action in skeletal
muscleviadirectphosphorylationofPGC-1α,” Proceedingsof
the National Academy of Sciences of the United States of Amer-
ica, vol. 104, no. 29, pp. 12017–12022, 2007.
[36] R. C. Scarpulla, “Metabolic control of mitochondrial bio-
genesis through the PGC-1 family regulatory network,” Bio-
chimica et Biophysica Acta, vol. 1813, no. 7, pp. 1269–1278,
2011.
[37] S. A. Hawley, J. Boudeau, J. L. Reid et al., “Complexes bet-
ween the LKB1 tumor suppressor, STRADα/β and MO25α/β
are upstream kinases in the AMP-activated protein kinase
cascade,” Journal of Biology, vol. 2, no. 4, article 28, 2003.
[ 3 8 ]S .A .H a w l e y ,D .A .P a n ,K .J .M u s t a r de ta l . ,“ C a l m o d u l i n -
dependent protein kinase kinase-β is an alternative upstream
kinase for AMP-activated protein kinase,” Cell Metabolism,
vol. 2, no. 1, pp. 9–19, 2005.
[39] R. L. Hurley, K. A. Anderson, J. M. Franzone, B. E. Kemp, A.
R.Means,andL.A.Witters,“TheCa2+/calmodulin-depend-
ent protein kinase kinases are AMP-activated protein kinase
kinases,” The Journal of Biological Chemistry, vol. 280, no. 32,
pp. 29060–29066, 2005.
[40] A. Woods, K. Dickerson, R. Heath et al., “Ca2+/calmodulin-
dependent protein kinase kinase-β acts upstream of AMP-
activated protein kinase in mammalian cells,” Cell Metabo-
lism, vol. 2, no. 1, pp. 21–33, 2005.
[41] A. Woods, S. R. Johnstone, K. Dickerson et al., “LKB1 is the
upstream kinase in the AMP-activated protein kinase cas-
cade,” Current Biology, vol. 13, no. 22, pp. 2004–2008, 2003.
[42] B. Mespl` es, F. Plaisant, R. H. Fontaine, and P. Gressens,
“Pathophysiologyofneonatalbrainlesions:lessonsfromani-
mal models of excitotoxicity,” Acta Paediatrica, International
Journal of Paediatrics, vol. 94, no. 2, pp. 185–190, 2005.
[43] C. G. Concannon, L. P. Tuﬀy, P. Weisov´ a et al., “AMP kinase-
mediated activation of the BH3-only protein Bim couples
energy depletion to stressinduced apoptosis,” Journal of Cell
Biology, vol. 189, no. 1, pp. 83–94, 2010.
[ 4 4 ]G .A .G u s a r o v a ,H .E .T r e j o ,L .A .D a d ae ta l . ,“ H y p o x i a
leads to Na,K-ATPase downregulation via Ca2+ release-acti-
vated Ca2+ channels and AMPK activation,” Molecular and
Cellular Biology, vol. 31, no. 17, pp. 3546–3556, 2011.
[45] P. T. Mungai, G. B. Waypa, A. Jairaman et al., “Hypoxia
triggers AMPK activation through reactive oxygen species-
mediated activation of calcium release-activated calcium
channels,” Molecular and Cellular Biology, vol. 31, no. 17, pp.
3531–3545, 2011.
[46] J. Li, Z. Zeng, B. Viollet, G. V. Ronnett, and L. D. McCul-
lough, “Neuroprotective eﬀects of adenosine monophos-
phate-activated protein kinase inhibition and gene deletion
in stroke,” Stroke, vol. 38, no. 11, pp. 2992–2999, 2007.
[47] L.D.McCullough,Z.Zeng,H.Li,L.E.Landree,J.McFadden,
andG.V.Ronnett,“PharmacologicalinhibitionofAMP-acti-
vatedproteinkinaseprovidesneuroprotectioninstroke,”The
Journal of Biological Chemistry, vol. 280, no. 21, pp. 20493–
20502, 2005.
[48] A. Tanaka and R. J. Youle, “A chemical inhibitor of DRP1 un-
couples mitochondrial ﬁssion and apoptosis,” Molecular Cell,
vol. 29, no. 4, pp. 409–410, 2008.12 Neurology Research International
[49] A. Cassidy-Stone, J. E. Chipuk, E. Ingerman et al., “Chemical
inhibition of the mitochondrial division dynamin reveals its
role in Bax/Bak-dependent mitochondrial outer membrane
permeabilization,” Developmental Cell,v o l .1 4 ,n o .2 ,p p .
193–204, 2008.
[50] M. Vila and S. Przedborski, “Targeting programmed cell
death in neurodegenerative diseases,” Nature Reviews Neuro-
science, vol. 4, no. 5, pp. 365–375, 2003.
[51] D. R. Green, “Apoptotic pathways: paper wraps stone blunts
scissors,” Cell, vol. 102, no. 1, pp. 1–4, 2000.
[52] L. Y. Li, X. Luo, and X. Wang, “Endonuclease G is an apop-
totic DNase when released from mitochondria,” Nature, vol.
412, no. 6842, pp. 95–99, 2001.
[53] S. A. Susin, H. K. Lorenzo, N. Zamzami et al., “Molecular
characterization of mitochodrial apoptosis-inducing factor,”
Nature, vol. 397, no. 6718, pp. 441–446, 1999.
[54] C. M. Troy, N. Akpan, and Y. Y. Jean, “Regulation of caspases
in the nervous system: implications for functions in health
and disease,” Progress in Molecular Biology and Translational
Science, vol. 99, pp. 265–305, 2011.
[55] S. B. Bratton and G. S. Salvesen, “Regulation of the Apaf-1-
caspase-9 apoptosome,” Journal of Cell Science, vol. 123, no.
19, pp. 3209–3214, 2010.
[ 5 6 ]B .R .S .B r o u g h t o n ,D .C .R e u t e n s ,a n dC .G .S o b e y ,“ A p o p -
totic mechanisms after cerebral ischemia,” Stroke, vol. 40, no.
5, pp. e331–e339, 2009.
[57] N. Bulat and C. Widmann, “Caspase substrates and neurode-
generative diseases,” Brain Research Bulletin,v o l .8 0 ,n o .4 - 5 ,
pp. 251–267, 2009.
[58] T.-J. Fan, L.-H. Han, R.-S. Cong, and J. Liang, “Caspase fam-
ily proteases and apoptosis,” Acta Biochimica et Biophysica
Sinica, vol. 37, no. 11, pp. 719–727, 2005.
[59] F. J. Northington, R. Chavez-Valdez, and L. J. Martin, “Neu-
ronal cell death in neonatal hypoxia-ischemia,” Annals of
Neurology, vol. 69, no. 5, pp. 743–758, 2011.
[60] C. Zhu, X. Wang, F. Xu et al., “The inﬂuence of age on
apoptotic and other mechanisms of cell death after cerebral
hypoxia-ischemia,”CellDeathandDiﬀerentiation,vol.12,no.
2, pp. 162–176, 2005.
[61] J. R. Leonard, B. J. Klocke, C. D’sa, R. A. Flavell, and K. A.
Roth, “Strain-dependent neurodevelopmental abnormalities
in caspase-3-deﬁcient mice,” Journal of Neuropathology and
Experimental Neurology, vol. 61, no. 8, pp. 673–677, 2002.
[62] T. West, M. Atzeva, and D. M. Holtzman, “Caspase-3 deﬁ-
ciency during development increases vulnerability to hypo-
xic-ischemic injury through caspase-3-independent path-
ways,” Neurobiology of Disease, vol. 22, no. 3, pp. 523–537,
2006.
[63] X. Wang, J. O. Karlsson, C. Zhu, B. A. Bahr, H. Hagberg,
and K. Blomgren, “Caspase-3 activation after neonatal rat
cerebral hypoxia-ischemia,” Biology of the Neonate, vol. 79,
no. 3-4, pp. 172–179, 2001.
[64] M. D’Amelio, V. Cavallucci, and F. Cecconi, “Neuronal
caspase-3 signaling: not only cell death,” Cell Death and Dif-
ferentiation, vol. 17, no. 7, pp. 1104–1114, 2010.
[65] P. P. Monnier, P. M. D’Onofrio, M. Magharious et al., “In-
volvement of caspase-6 and caspase-8 in neuronal apoptosis
and the regenerative failure of injured retinal ganglion cells,”
Journal of Neuroscience, vol. 31, no. 29, pp. 10494–10505,
2011.
[66] N. Akpan, E. Serrano-Saiz, B. E. Zacharia et al., “Intranasal
delivery of caspase-9 inhibitor reduces caspase-6-dependent
axon/neuron loss and improves neurological function after
stroke,” Journal of Neuroscience, vol. 31, no. 24, pp. 8894–
8904, 2011.
[67] A. Nikolaev, T. McLaughlin, D. D. M. O’Leary, and M.
Tessier-Lavigne, “APP binds DR6 to trigger axon pruning
and neuron death via distinct caspases,” Nature, vol. 457, no.
7232, pp. 981–989, 2009.
[68] J. E. Chipuk and D. R. Green, “How do BCL-2 proteins
induce mitochondrial outer membrane permeabilization?”
Trends in Cell Biology, vol. 18, no. 4, pp. 157–164, 2008.
[69] A. Rasola, M. Sciacovelli, B. Pantic, and P. Bernardi, “Signal
transduction to the permeability transition pore,” FEBS
Letters, vol. 584, no. 10, pp. 1989–1996, 2010.
[70] A. C. Schinzel, O. Takeuchi, Z. Huang et al., “Cyclophilin D is
a component of mitochondrial permeability transition and
m e d i a t e sn e u r o n a lc e l ld e a t ha f t e rf o c a lc e r e b r a li s c h e m i a , ”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 102, no. 34, pp. 12005–12010, 2005.
[71] X. Wang, Y. Carlsson, E. Basso et al., “Developmental shift of
cyclophilin D contribution to hypoxic-ischemic brain inju-
ry,” Journal of Neuroscience, vol. 29, no. 8, pp. 2588–2596,
2009.
[ 7 2 ]M .E .G i b s o n ,H .H .B y u n g ,J .C h o ie ta l . ,“ B A Xc o n -
tributes to apoptotic-like death following neonatal hypoxia-
ischemia: evidence for distinct apoptosis pathways,” Molecu-
lar Medicine, vol. 7, no. 9, pp. 644–655, 2001.
[73] J. M. Ness, C. A. Harvey, A. Strasser, P. Bouillet, B. J. Klocke,
and K. A. Roth, “Selective involvement of BH3-only Bcl-2
familymembersBimandBadinneonatalhypoxia-ischemia,”
Brain Research, vol. 1099, no. 1, pp. 150–159, 2006.
[74] W. Yin, G. Cao, M. J. Johnnides et al., “TAT-mediated
delivery of Bcl-xL protein is neuroprotective against neonatal
hypoxic-ischemic brain injury via inhibition of caspases and
AIF,” Neurobiology of Disease, vol. 21, no. 2, pp. 358–371,
2006.
[75] A. S. Parsadanian, Y. Cheng, C. R. Keller-Peck, D. M. Holtz-
man, and W. D. Snider, “Bcl-x(L) is an antiapoptotic regula-
tor for postnatal CNS neurons,” Journal of Neuroscience, vol.
18, no. 3, pp. 1009–1019, 1998.
[76] X. Wang, W. Han, X. Du et al., “Neuroprotective eﬀect of
Bax-inhibiting peptide on neonatal brain injury,” Stroke, vol.
41, no. 9, pp. 2050–2055, 2010.
[77] K. H. Vousden and C. Prives, “Blinded by the Light: the
Growing Complexity of p53,” Cell, vol. 137, no. 3, pp. 413–
431, 2009.
[78] R. S. Morrison, Y. Kinoshita, M. D. Johnson, W. Guo, and G.
A. Garden, “p53-dependent cell death signaling in neurons,”
Neurochemical Research, vol. 28, no. 1, pp. 15–27, 2003.
[79] D. R. Green and G. Kroemer, “Cytoplasmic functions of
the tumour suppressor p53,” Nature, vol. 458, no. 7242, pp.
1127–1130, 2009.
[80] R. Honda, H. Tanaka, and H. Yasuda, “Oncoprotein MDM2
is a ubiquitin ligase E3 for tumor suppressor p53,” FEBS Let-
ters, vol. 420, no. 1, pp. 25–27, 1997.
[81] T. Riley, E. Sontag, P. Chen, and A. Levine, “Transcriptional
control of human p53-regulated genes,” Nature Reviews Mol-
ecular Cell Biology, vol. 9, no. 5, pp. 402–412, 2008.
[82] J.E.Chipuk,L.Bouchier-Hayes,T.Kuwana,D.D.Newmeyer,
and D. R. Green, “Cell biology: PUMA couples the nuclear
and cytoplasmic proapoptotic function of p53,” Science, vol.
309, no. 5741, pp. 1732–1735, 2005.
[83] C. H. A. Nijboer, C. J. Heijnen, F. Groenendaal, M. J. May, F.
van Bel, and A. Kavelaars, “Strong neuroprotection by inhi-
bition of NF-μ◦B after neonatal hypoxia-ischemia involvesNeurology Research International 13
apoptotic mechanisms but is independent of cytokines,”
Stroke, vol. 39, no. 7, pp. 2129–2137, 2008.
[84] C.H. Nijboer, C.J.Heijnen, F. Groenendaal, M.J. May, F. van
Bel, and A. Kavelaars, “A dual role of the nf-kappa b pathway
in neonatal hypoxic-ischemic brain damage,” Stroke, vol. 39,
no. 9, pp. 2578–2586, 2008.
[85] M. A. van der Kooij, C. H. Nijboer, F. Ohl et al., “NF-κB
inhibitionafterneonatalcerebralhypoxia-ischemiaimproves
long-term motor and cognitive outcome in rats,” Neurobiol-
ogy of Disease, vol. 38, no. 2, pp. 266–272, 2010.
[86] C. H. Nijboer, C. J. Heijnen, M. A. van der Kooij et al.,
“Targeting the p53 pathway to protect the neonatal ischemic
brain,” Annals of Neurology, vol. 70, no. 2, pp. 255–264, 2011.
[87] E. Strom, S. Sathe, P. G. Komarov et al., “Small-molecule
inhibitor of p53 binding to mitochondria protects mice from
gamma radiation,” Nature Chemical Biology,v o l .2 ,n o .9 ,p p .
474–479, 2006.
[88] S. C. Dreskin, G. W. Thomas, S. N. Dale, and L. E. Heasley,
“Isoforms of jun kinase are diﬀerentially expressed and ac-
tivated in human monocyte/macrophage (THP-1) cells1,”
Journal of Immunology, vol. 166, no. 9, pp. 5646–5653, 2001.
[89] C. Y. Kuan, A. J. Whitmarsh, D. D. Yang et al., “A critical role
of neural-speciﬁc JNK3 for ischemic apoptosis,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 100, no. 25, pp. 15184–15189, 2003.
[90] G.Pirianov,K.G.Brywe,C.Mallardetal.,“Deletionofthec-
Jun N-terminal kinase 3 gene protects neonatal mice against
cerebral hypoxic-ischaemic injury,” Journal of Cerebral Blood
Flow and Metabolism, vol. 27, no. 5, pp. 1022–1032, 2007.
[91] T. Herdegen, F. X. Claret, T. Kallunki et al., “Lasting N-
terminal phosphorylation of c-Jun and activation of c-Jun
N- terminal kinases after neuronal injury,” Journal of Neuro-
science, vol. 18, no. 14, pp. 5124–5135, 1998.
[92] S. Kumar, M. Kinoshita, M. Noda, N. G. Copeland, and N. A.
Jenkins, “Induction of apoptosis by the mouse Nedd2 gene,
whichencodesaproteinsimilartotheproductoftheCaenor-
habditiseleganscelldeathgeneced-3andthemammalianIL-
1β-converting enzyme,” Genes and Development, vol. 8, no.
14, pp. 1613–1626, 1994.
[93] H. Duan and V. M. Dixit, “RAIDD is a new ’death’ adaptor
molecule,” Nature, vol. 385, no. 6611, pp. 86–89, 1997.
[94] B. C. Baliga, S. H. Read, and S. Kumar, “The biochemical
mechanism of caspase-2 activation,” Cell Death and Diﬀer-
entiation, vol. 11, no. 11, pp. 1234–1241, 2004.
[95] A. Tinel and J. Tschopp, “The PIDDosome, a protein com-
plex implicated in activation of caspase-2 in response to gen-
otoxic stress,” Science, vol. 304, no. 5672, pp. 843–846, 2004.
[96] P. Lassus, X. Opitz-Araya, and Y. Lazebnik, “Requirement for
caspase-2 in stress-induced apoptosis before mitochondrial
permeabilization,”Science,vol.297,no.5585,pp.1352–1354,
2002.
[97] Y. Carlsson, L. Schwendimann, R. Vontell et al., “Genetic
inhibition of caspase-2 reduces hypoxic-ischemic and exci-
totoxic neonatal brain injury,” Annals of Neurology, vol. 70,
no. 5, pp. 781–789, 2011.
[ 9 8 ] L .B e r g e r o n ,G .I .P e r e z ,G .M a c d o n a l de ta l . ,“ D e f e c t si nr e g -
ulation of apoptosis in caspase-2-deﬁcient mice,” Genes and
Development, vol. 12, no. 9, pp. 1304–1314, 1998.
[99] D. Chauvier, S. Renolleau, S. Holifanjaniaina et al., “Target-
ingneonatalischemicbraininjurywithapentapeptide-based
irreversible caspase inhibitor,” Cell Death and Disease, vol. 2,
no. 9, article e203, 2011.
[100] Y. Jin, A. J. Silverman, and S. J. Vannucci, “Mast cells are early
responders after hypoxia-ischemia in immature rat brain,”
Stroke, vol. 40, no. 9, pp. 3107–3112, 2009.
[101] H. Hagberg and C. Mallard, “Eﬀect of inﬂammation on
central nervous system development and vulnerability,” Cur-
rent Opinion in Neurology, vol. 18, no. 2, pp. 117–123, 2005.
[102] E. Bona, A. L. Andersson, K. Blomgren et al., “Chemokine
and inﬂammatory cell response to hypoxia-ischemia in im-
mature rats,” Pediatric Research, vol. 45, no. 4, pp. 500–509,
1999.
[103] D. L. Taylor, F. Jones, E. S. F. Chen Seho Kubota, and J. M.
Pocock, “Stimulation of microglial metabotropic glutamate
receptor mGlu2 triggers tumor necrosis factor α-induced
neurotoxicity in concert with microglial-derived Fas ligand,”
Journal of Neuroscience, vol. 25, no. 11, pp. 2952–2964, 2005.
[104] O. Hoﬀmann, F. Zipp, and J. R. Weber, “Tumour necrosis
factor-related apoptosis-inducing ligand (TRAIL) in central
nervous system inﬂammation,” Journal of Molecular Medi-
cine, vol. 87, no. 8, pp. 753–763, 2009.
[105] M. Yepes, S. A. N. Brown, E. G. Moore, E. P. Smith, D.
A. Lawrence, and J. A. Winkles, “A soluble Fn14-Fc decoy
receptor reduces infarct volume in a murine model of cere-
bral ischemia,” American Journal of Pathology, vol. 166, no. 2,
pp. 511–520, 2005.
[106] A. D. Edwards, X. Yue, P. Cox et al., “Apoptosis in the brains
ofinfantssuﬀeringintrauterinecerebralinjury,”PediatricRe-
search, vol. 42, no. 5, pp. 684–689, 1997.
[107] D. Pennica, G. E. Nedwin, and J. S. Hayﬂick, “Human
tumour necrosis factor: precursor structure, expression and
homology to lymphotoxin,” Nature, vol. 312, no. 5996, pp.
724–729, 1984.
[108] S. Love, “Apoptosis and brain ischaemia,” Progress in Neuro-
Psychopharmacology and Biological Psychiatry,v o l .2 7 ,n o .2 ,
pp. 267–282, 2003.
[109] T. Sugawara, M. Fujimura, N. Noshita et al., “Neuronal
death/survival signaling pathways in cerebral ischemia,”
NeuroRx, vol. 1, no. 1, pp. 17–25, 2004.
[110] P. Vandenabeele, L. Galluzzi, T. Vanden Berghe, and G.
Kroemer, “Molecular mechanisms of necroptosis: an ordered
cellular explosion,” Nature Reviews Molecular Cell Biology,
vol. 11, no. 10, pp. 700–714, 2010.
[111] L. A. Tartaglia, R. F. Weber, I. S. Figari, C. Reynolds, M. A.
Palladino, and D. V. Goeddel, “The two diﬀerent receptors
fortumornecrosisfactormediatedistinctcellularresponses,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 88, no. 20, pp. 9292–9296, 1991.
[112] D. Dziewulska and M. J. Mossakowski, “Cellular expression
of tumor necrosis factor α and its receptors in human
ischemic stroke,” Clinical Neuropathology,v o l .2 2 ,n o .1 ,p p .
35–40, 2003.
[113] I. Figiel and K. Dzwonek, “TNFα and TNF receptor 1 expres-
sion in the mixed neuronal-glial cultures of hippocampal
dentate gyrus exposed to glutamate or trimethyltin,” Brain
Research, vol. 1131, no. 1, pp. 17–28, 2007.
[114] J. M. Dopp, A. Mackenzie-Graham, G. C. Otero, and J. E.
Merrill, “Diﬀerential expression, cytokine modulation, and
speciﬁc functions of type-1 and type-2 tumor necrosis factor
receptors in rat glia,” Journal of Neuroimmunology, vol. 75,
no. 1-2, pp. 104–112, 1997.
[115] Z. Dembic, H. Loetscher, U. Gubler et al., “Two human TNF
receptors have similar extracellular, but distinct intracellular,
domainsequences,”Cytokine,vol.2,no.4,pp.231–237,1990.
[116] L. Marchetti, M. Klein, K. Schlett, K. Pﬁzenmaier, and
U. L. M. Eisel, “Tumor necrosis factor (TNF)-mediated14 Neurology Research International
neuroprotection against glutamate-induced excitotoxicity is
enhanced by N-methyl-D-aspartate receptor activation: es-
sential role of a TNF receptor 2-mediated phosphatidyli-
nositol 3-kinase-dependent NF-κBp a t h w a y , ”The Journal of
BiologicalChemistry,vol.279,no.31,pp.32869–32881,2004.
[117] H. Hsu, J. Xiong, and D. V. Goeddel, “The TNF receptor
1-associated protein TRADD signals cell death and NF-κB
activation,” Cell, vol. 81, no. 4, pp. 495–504, 1995.
[118] H. Y. Song, C. H. R´ egnier, C. J. Kirschning, D. V. Goeddel,
and M. Rothe, “Tumor necrosis factor (TNF)-mediated kin-
ase cascades: bifurcation of nuclear factor-κB and c-jun N-
terminal kinase (JNK/SAPK) pathways at TNF receptor-
associated factor 2,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 94, no. 18, pp.
9792–9796, 1997.
[119] K. B. Nelson, J. M. Dambrosia, J. K. Grether, and T. M.
Phillips, “Neonatal cytokines and coagulation factors in chil-
dren with cerebral palsy,” Annals of Neurology, vol. 44, no. 4,
pp. 665–675, 1998.
[120] T. Markus, T. Cronberg, C. Cilio, C. Pronk, T. Wieloch, and
D. Ley, “Tumor necrosis factor receptor-1 is essential for
LPS-induced sensitization and tolerance to oxygen-glucose
deprivation in murine neonatal organotypic hippocampal
slices,” Journal of Cerebral Blood Flow and Metabolism, vol.
29, no. 1, pp. 73–86, 2009.
[121] G. S. Kendall, M. Hirstova, S. Horn et al., “TNF gene cluster
deletion abolishes lipopolysaccharide-mediated sensitization
of the neonatal brain to hypoxic ischemic insult,” Laboratory
Investigation, vol. 91, no. 3, pp. 328–341, 2011.
[122] C. Yu, M. Takeda, and B. Soliven, “Regulation of cell cycle
proteinsbyTNF-αandTGF-β incellsofoligodendrogliallin-
eage,” Journal of Neuroimmunology, vol. 108, no. 1-2, pp. 2–
10, 2000.
[123] T. Andrews, P. Zhang, and N. R. Bhat, “TNFα potentiates
IFNγ-induced cell death in oligodendrocyte progenitors,”
Journal of Neuroscience Research, vol. 54, no. 5, pp. 574–583,
1998.
[124] K. W. Selmaj, M. Farooq, W. T. Norton, C. S. Raine, and C.
F. Brosnan, “Proliferation of astrocytes in vitro in response to
cytokines. A primary role for tumor necrosis factor,” Journal
of Immunology, vol. 144, no. 1, pp. 129–135, 1990.
[125] H. Takeuchi, S. Jin, J. Wang et al., “Tumor necrosis factor-α
induces neurotoxicity via glutamate release from hemichan-
nels of activated microglia in an autocrine manner,” The
Journal of Biological Chemistry, vol. 281, no. 30, pp. 21362–
21368, 2006.
[126] A. J. Bruce, W. Boling, M. S. Kindy et al., “Altered neuronal
and microglial responses to excitotoxic and ischemic brain
injury in mice lacking TNF receptors,” Nature Medicine, vol.
2, no. 7, pp. 788–794, 1996.
[127] K. L. Lambertsen, B. H. Clausen, A. A. Babcock et al.,
“Microglia protect neurons against ischemia by synthesis of
t u m o rn e c r o s i sf a c t o r , ”Journal of Neuroscience, vol. 29, no. 5,
pp. 1319–1330, 2009.
[128] R. M. Pitti, S. A. Marsters, D. A. Lawrence et al., “Genomic
ampliﬁcation of a decoy receptor for Fas ligand in lung and
colon cancer,” Nature, vol. 396, no. 6712, pp. 699–703, 1998.
[129] A. Martin-Villalba, I. Herr, I. Jeremias et al., “CD95 ligand
(Fas-L/APO-1L) and tumor necrosis factor-related apop-
tosis- inducing ligand mediate ischemia-induced apoptosis
inneurons,”JournalofNeuroscience,vol.19,no.10,pp.3809–
3817, 1999.
[130] D. M. Rosenbaum, G. Gupta, J. D’Amore et al., “Fas
(CD95/APO-1) plays a role in the pathophysiology of focal
cerebral ischemia,” Journal of Neuroscience Research, vol. 61,
no. 6, pp. 686–692, 2000.
[131] F.J.Northington,D.M.Ferriero,D.L.Flock,andL.J.Martin,
“Delayed neurodegeneration in neonatal rat thalamus after
hypoxia-ischemia is apoptosis,” Journal of Neuroscience, vol.
21, no. 6, pp. 1931–1938, 2001.
[132] U. Felderhoﬀ-Mueser, D. L. Taylor, K. Greenwood et al.,
“Fas/CD95/APO-1 can function as a death receptor for neu-
ronal cells in vitro and in vivo and is upregulated following
cerebralhypoxic-ischemicinjurytothedevelopingratbrain,”
Brain Pathology, vol. 10, no. 1, pp. 17–29, 2000.
[133] E. M. Graham, R. A. Sheldon, D. L. Flock et al., “Neonatal
mice lacking functional Fas death receptors are resistant to
hypoxic-ischemic brain injury,” Neurobiology of Disease, vol.
17, no. 1, pp. 89–98, 2004.
[134] N. Holler, R. Zaru, O. Micheau et al., “Fas triggers an
alternative, caspase-8-independent cell death pathway using
thekinaseRIPaseﬀectormolecule,”NatureImmunology,vol.
1, no. 6, pp. 489–495, 2000.
[135] H. Matsumura, Y. Shimizu, Y. Ohsawa, A. Kawahara, Y.
Uchiyama, and S. Nagata, “Necrotic death pathway in Fas re-
ceptor signaling,” Journal of Cell Biology, vol. 151, no. 6, pp.
1247–1255, 2000.
[136] C. Lambert, A. M. Landau, and J. Desbarats, “Fas—beyond
death: a regenerative role for Fas in the nervous system,”
Apoptosis, vol. 8, no. 6, pp. 551–562, 2003.
[137] G. Pan, K. O’Rourke, A. M. Chinnaiyan et al., “The receptor
for the cytotoxic ligand TRAIL,” Science, vol. 276, no. 5309,
pp. 111–113, 1997.
[138] H.Walczak,M.A.Degli-Esposti,R.S.Johnsonetal.,“TRAIL-
R2: a novel apoptosis-mediating receptor for TRAIL,” The
EMBO Journal, vol. 16, no. 17, pp. 5386–5397, 1997.
[139] J. P. Sheridan, S. A. Marsters, R. M. Pitti et al., “Control of
TRAIL-induced apoptosis by a family of signaling and decoy
receptors,” Science, vol. 277, no. 5327, pp. 818–821, 1997.
[140] S.A.Marsters,J.P.Sheridan,R.M.Pittietal.,“A novelrecep-
tor for Apo2L/TRAIL contains a truncated death domain,”
Current Biology, vol. 7, no. 12, pp. 1003–1006, 1997.
[141] J. G. Emery, P. McDonnell, M. B. Burke et al., “Osteoprote-
gerin is a receptor for the cytotoxic ligand TRAIL,” The Jour-
nalofBiologicalChemistry,vol.273,no.23,pp.14363–14367,
1998.
[142] C.Bossen,K.Ingold,A.Tardiveletal.,“Interactionsoftumor
necrosis factor (TNF) and TNF receptor family members in
the mouse and human,” The Journal of Biological Chemistry,
vol. 281, no. 20, pp. 13964–13971, 2006.
[143] P. Schneider, D. Olson, A. Tardivel et al., “Identiﬁcation of a
new murine tumor necrosis factor receptor locus that con-
tains two novel murine receptors for tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL),” The Journal of
Biological Chemistry, vol. 278, no. 7, pp. 5444–5454, 2003.
[144] G. S. Wu, T. F. Burns, Y. Zhan, E. S. Alnemri, and W.
S. El-Deiry, “Molecular cloning and functional analysis of
the mouse homologue of the KILLER/DR5 tumor necro-
sis factor-related apoptosis-inducing ligand (TRAIL) death
receptor,” Cancer Research, vol. 59, no. 12, pp. 2770–2775,
1999.
[145] S. R. Wiley, L. Cassiano, T. Lofton et al., “A novel TNF
receptor family member binds TWEAK and is implicated in
angiogenesis,” Immunity, vol. 15, no. 5, pp. 837–846, 2001.
[146] J. A. Winkles, “The TWEAK-Fn14 cytokine-receptor axis:
discovery, biology andtherapeutic targeting,”Nature Reviews
Drug Discovery, vol. 7, no. 5, pp. 411–425, 2008.Neurology Research International 15
[147] M. Nakayama, K. Ishidoh, N. Kayagaki et al., “Multiple path-
ways of TWEAK-induced cell death,” Journal of Immunology,
vol. 168, no. 2, pp. 734–743, 2002.
[148] I. Potrovita, W. Zhang, L. Burkly et al., “Tumor necrosis
factor-likeweakinducerofapoptosis-inducedneurodegener-
ation,”JournalofNeuroscience,vol.24,no.38,pp.8237–8244,
2004.
[149] B. Cannella, S. Gaupp, K. M. Omari, and C. S. Raine,
“Multiple sclerosis: death receptor expression and oligoden-
drocyte apoptosis in established lesions,” Journal of Neuroim-
munology, vol. 188, no. 1-2, pp. 128–137, 2007.
[150] M. Cui, L. Wang, X. Liang et al., “Blocking TRAIL-DR5
signalingwithsolubleDR5reducesdelayedneuronaldamage
after transient global cerebral ischemia,” Neurobiology of Dis-
ease, vol. 39, no. 2, pp. 138–147, 2010.
[151] G. Favrais, Y. van de Looij, B. Fleiss et al., “Systemic inﬂam-
mation disrupts the developmental program of white mat-
ter,” Annals of Neurology, vol. 70, no. 4, pp. 550–565, 2011.
[152] M. A. Galic, K. Riazi, J. G. Heida et al., “Postnatal inﬂamma-
tion increases seizure susceptibility in adult rats,” Journal of
Neuroscience, vol. 28, no. 27, pp. 6904–6913, 2008.
[153] S. J. Spencer, R. N. Auer, and Q. J. Pittman, “Rat neonatal
immune challenge alters adult responses to cerebral ischae-
mia,” Journal of Cerebral Blood Flow and Metabolism, vol. 26,
no. 4, pp. 456–467, 2006.
[154] S. D. Bilbo, R. M. Barrientos, A. S. Eads et al., “Early-life
infection leads to altered BDNF and IL-1β mRNA expression
in rat hippocampus following learning in adulthood,” Brain,
Behavior, and Immunity, vol. 22, no. 4, pp. 451–455, 2008.
[155] C. Y. Lin, Y. C. Chang, S. T. Wang, T. Y. Lee, C. F. Lin, and
C. C. Huang, “Altered inﬂammatory responses in preterm
children with cerebral palsy,” Annals of Neurology, vol. 68, no.
2, pp. 204–212, 2010.
[156] K. Nagamoto-Combs, D. W. McNeal, R. J. Morecraft, and
C. K. Combs, “Prolonged microgliosis in the rhesus monkey
central nervous system after traumatic brain injury,” Journal
of Neurotrauma, vol. 24, no. 11, pp. 1719–1742, 2007.
[157] J. F. Annegers and W. A. Rocca, “Causes of epilepsy: contri-
butions of the rochester epidemiology project,” Mayo Clinic
Proceedings, vol. 71, no. 6, pp. 570–575, 1996.
[158] C. Limperopoulos, H. Bassan, N. R. Sullivan et al., “Positive
screening for autism in ex-preterm infants: prevalence and
risk factors,” Pediatrics, vol. 121, no. 4, pp. 758–765, 2008.
[159] U. Meyer, J. Feldon, and O. Dammann, “Schizophrenia and
autism: both shared and disorder-speciﬁc pathogenesis via
perinatal inﬂammation?” Pediatric Research, vol. 69, no. 5,
part 2, pp. 26R–33R, 2011.
[160] M. Thoresen, “Cooling the newborn after asphyxia—physio-
logical and experimental background and its clinical use,”
Seminars in Neonatology, vol. 5, no. 1, pp. 61–73, 2000.
[161] Y. Liu, J. D. Barks, G. Xu, and F. S. Silverstein, “Topiramate
extends the therapeutic window for hypothermia-mediated
neuroprotection after stroke in neonatal rats,” Stroke, vol. 35,
no. 6, pp. 1460–1465, 2004.
[162] J. D. Barks, Y. Q. Liu, Y. Shangguan, and F. S. Silverstein,
“Phenobarbital augments hypothermic neuroprotection,”
Pediatric Research, vol. 67, no. 5, pp. 532–537, 2010.
[163] D. Ma, M. Hossain, A. Chow et al., “Xenon and hypothermia
combine to provide neuroprotection from neonatal asphyx-
ia,” Annals of Neurology, vol. 58, no. 2, pp. 182–193, 2005.
[164] S. Faulkner, A. Bainbridge, T. Kato et al., “Xenon augmented
hypothermia reduces early lactate/N-acetylaspartate and cell
death in perinatal asphyxia,” Annals of Neurology, vol. 70, no.
1, pp. 133–150, 2011.
[165] M. Rogido, I. Husson, C. Bonnier et al., “Fructose-1,6-
biphosphate prevents excitotoxic neuronal cell death in the
neonatal mouse brain,” Developmental Brain Research, vol.
140, no. 2, pp. 287–297, 2003.
[166] A. F. Ramlackhansingh, D. J. Brooks, R. J. Greenwood et al.,
“Inﬂammation after trauma: microglial activation and trau-
matic brain injury,” Annals of Neurology, vol. 70, no. 3, pp.
374–383, 2011.
[167] I. C. G. Weaver, N. Cervoni, F. A. Champagne et al., “Epige-
netic programming by maternal behavior,” Nature Neurosci-
ence, vol. 7, no. 8, pp. 847–854, 2004.
[168] M. Ren, Y. Leng, M. Jeong, P. R. Leeds, and D. M. Chuang,
“Valproic acid reduces brain damage induced by transient
focal cerebral ischemia in rats: potential roles of histone
deacetylase inhibition and heat shock protein induction,”
Journal of Neurochemistry, vol. 89, no. 6, pp. 1358–1367,
2004.
[169] G. Faraco, T. Pancani, L. Formentini et al., “Pharmacological
inhibition of histone deacetylases by suberoylanilide hydrox-
amic acid speciﬁcally alters gene expression and reduces is-
chemic injury in the mouse brain,” Molecular Pharmacol-
ogy, vol. 70, no. 6, pp. 1876–1884, 2006.
[170] X. Ke, Q. Lei, S. J. James et al., “Uteroplacental insuﬃciency
aﬀects epigenetic determinants of chromatin structure in
brains of neonatal and juvenile IUGR rats,” Physiological Ge-
nomics, vol. 25, no. 1, pp. 16–28, 2006.
[171] S. Shen, A. Liu, J. Li, C. Wolubah, and P. Casaccia-Bonneﬁl,
“Epigenetic memory loss in aging oligodendrocytes in the
corpus callosum,” Neurobiology of Aging,v o l .2 9 ,n o .3 ,p p .
452–463, 2008.
[172] S. N. Jai, R. P. Sharma, M. Veldic et al., “DNA methyltrans-
ferase 1 regulates reelin mRNA expression in mouse primary
cortical cultures,” Proceedings of the National Academy of Sci-
encesoftheUnitedStatesofAmerica,vol.102,no.5,pp.1749–
1754, 2005.
[173] A. Yakovlev, M. Khaﬁzova, Z. Abdullaev, D. Loukinov, and A.
Kondratyev, “Epigenetic regulation of caspase-3 gene expres-
sioninratbraindevelopment,”Gene,vol.450,no.1-2,Article
ID 36651, pp. 103–108, 2010.
[174] J. Liu and P. Casaccia, “Epigenetic regulation of oligodendro-
cyte identity,” Trends in Neurosciences, vol. 33, no. 4, pp. 193–
201, 2010.
[175] F. Ye, Y. Chen, T. Hoang et al., “HDAC1 and HDAC2 regu-
late oligodendrocyte diﬀerentiation by disrupting the beta-
catenin-TCF interaction,” Nature Neuroscience, vol. 12, no. 7,
pp. 829–838, 2009.
[176] A. Dharap, K. Bowen, R. Place, L.-C. Li, and R. Vemuganti,
“Transientfocalischemiainducesextensivetemporalchanges
in rat cerebral MicroRNAome,” Journal of Cerebral Blood
Flow and Metabolism, vol. 29, no. 4, pp. 675–687, 2009.
[177] E. D. Ponomarev, T. Veremeyko, N. Barteneva, A. M. Krich-
evsky,andH.L.Weiner,“MicroRNA-124promotesmicroglia
quiescence and suppresses EAE by deactivating macrophages
viatheC/EBP-α-PU.1pathway,” Nature Medicine,vol. 17,no.
1, pp. 64–70, 2010.
[178] C. L. Gibson and S. P. Murphy, “Beneﬁts of histone deacetyl-
ase inhibitors for acute brain injury: a systematic review of
animalstudies,”JournalofNeurochemistry,vol.115,no.4,pp.
806–813, 2010.
[179] N. Kabakus, I. Ay, S. Aysun, F. S¨ oylemezoglu, A. ¨ Ozcan, and
B. Celasun, “Protective eﬀects of valproic acid against hypo-
xic-ischemic brain injury in neonatal rats,” Journal of Child
Neurology, vol. 20, no. 7, pp. 582–587, 2005.16 Neurology Research International
[180] I. C. G. Weaver, F. A. Champagne, S. E. Brown et al.,
“Reversal of maternal programming of stress responses in
adult oﬀspring through methyl supplementation: altering
epigenetic marking later in life,” Journal of Neuroscience, vol.
25, no. 47, pp. 11045–11054, 2005.
[181] C. A. Colton, “Heterogeneity of microglial activation in the
innate immune response in the brain,” Journal of Neuroim-
mune Pharmacology, vol. 4, no. 4, pp. 399–418, 2009.
[182] C. A. Colton and D. M. Wilcock, “Assessing activation states
inmicroglia,”CNSandNeurologicalDisorders—DrugTargets,
vol. 9, no. 2, pp. 174–191, 2010.
[183] M. Lalancette-H´ ebert, G. Gowing, A. Simard, C. W. Yuan,
andJ.Kriz,“Selectiveablationofproliferatingmicroglialcells
exacerbates ischemicinjuryinthebrain,”J o urnalo fN eur osci-
ence, vol. 27, no. 10, pp. 2596–2605, 2007.
[184] A. Madinier, N. Bertrand, C. Mossiat et al., “Microglial
involvement in neuroplastic changes following focal brain
ischemia in rats,” PLoS One, vol. 4, no. 12, Article ID e8101,
2009.
[185] J. Mikita, N. Dubourdieu-Cassagno, M. S. Deloire et al.,
“Altered M1/M2 activation patterns of monocytes in severe
relapsing experimental rat model of multiple sclerosis. Amel-
ioration of clinical status by M2 activated monocyte admin-
istration,” Multiple Sclerosis, vol. 17, no. 1, pp. 2–15, 2011.
[186] L. Titomanlio, M. Bouslama, V. Le Verche et al., “Implanted
neurosphere-derived precursors promote recovery after neo-
natal excitotoxic brain injury,” Stem Cells and Development,
vol. 20, no. 5, pp. 865–879, 2011.
[187] L. Zhang, Y. Li, C. Zhang, M. Chopp, A. Gosiewska, and K.
Hong, “Delayed administration of human umbilical tissue-
derived cells improved neurological functional recovery in a
rodent model of focal ischemia,” Stroke,v o l .4 2 ,n o .5 ,p p .
1437–1444, 2011.
[188] O. Baud, J. L. Daire, Y. Dalmaz et al., “Gestational hypoxia
induces white matter damage in neonatal rats: a new model
ofperiventricularleukomalacia,”Brain Pathology, vol. 14, no.
1, pp. 1–10, 2004.
[189] M.Delcour,P.Olivier,C.Chambonetal.,“Neuroanatomical,
sensorimotor and cognitive deﬁcits in adult rats with white
matter injury following prenatal ischemia,” Brain Pathology,
vol. 22, no. 1, pp. 1–16, 2012.
[190] J. M. Perlman, “White matter injury in the preterm infant:
an important determination of abnormal neurodevelopment
outcome,” Early Human Development, vol. 53, no. 2, pp. 99–
120, 1998.
[191] C. I. Rousset, S. Chalon, S. Cantagrel et al., “Maternal
exposure to LPS induces hypomyelination in the internal
capsule and programmed cell death in the deep gray matter
in newborn rats,” Pediatric Research, vol. 59, no. 3, pp. 428–
433, 2006.
[192] J. Tønnesen, C. L. Parish, A. T. Sørensen et al., “Functional
integration of grafted neural stem cell-derived dopaminergic
neurons monitored by optogenetics in an in vitro Parkinson
model,” PLoS One, vol. 6, no. 3, Article ID e17560, 2011.
[193] J.E.CarrollandR.W.Mays,“Updateonstemcelltherapyfor
cerebral palsy,” Expert Opinion on Biological Therapy, vol. 11,
no. 4, pp. 463–471, 2011.
[194] M. V. Covey, Y. Jiang, V. V. Alli, Z. Yang, and S. W. Levison,
“Deﬁning the critical period for neocortical neurogenesis
afterpediatricbraininjury,”DevelopmentalNeuroscience,vol.
32, no. 5-6, pp. 488–498, 2010.
[195] D. M. Holtzman, R. A. Sheldon, W. Jaﬀe, Y. Cheng, and D.
M.Ferriero,“Nervegrowthfactorprotectstheneonatalbrain
against hypoxic-ischemic injury,” Annals of Neurology, vol.
39, no. 1, pp. 114–122, 1996.
[196] B. M. Johnston, E. C. Mallard, C. E. Williams, and P. D.
Gluckman, “Insulin-likegrowthfactor-1is apotent neuronal
rescue agent after hypoxic-lschemic injury in fetal lambs,”
The Journal of Clinical Investigation, vol. 97, no. 2, pp. 300–
308, 1996.
[197] P. Gressens, S. Marret, J. M. Hill et al., “Vasoactive intestinal
peptide prevents excitotoxic cell death in the murine devel-
oping brain,” The Journal of Clinical Investigation, vol. 100,
no. 2, pp. 390–397, 1997.
[198] I. Husson, C. M. Rangon, V. Leli` evre et al., “BDNF-induced
white matter neuroprotection and stage-dependent neuronal
survival following a neonatal excitotoxic challenge,” Cerebral
Cortex, vol. 15, no. 3, pp. 250–261, 2005.
[199] D. Osredkar, J. W. Sall, P. E. Bickler, and D. M. Ferriero,
“Erythropoietin promotes hippocampal neurogenesis in in
vitro models of neonatal stroke,”Neurobiology of Disease, vol.
38, no. 2, pp. 259–265, 2010.
[200] K. D. Destot-Wong, K. Liang, S. K. Gupta et al., “The AMPA
receptor positive allosteric modulator, S18986, is neuropro-
tective against neonatal excitotoxic and inﬂammatory brain
damage through BDNF synthesis,” Neuropharmacology, vol.
57, no. 3, pp. 277–286, 2009.
[201] A. K. Welin, P. Svedin, R. Lapatto et al., “Melatonin reduces
inﬂammation and cell death in white matter in the mid-
gestation fetal sheep following umbilical cord occlusion,”
Pediatric Research, vol. 61, no. 2, pp. 153–158, 2007.
[202] E. Gitto, R. J. Reiter, A. Amodio et al., “Early indicators
of chronic lung disease in preterm infants with respiratory
distresssyndromeandtheirinhibitionbymelatonin,”Journal
of Pineal Research, vol. 36, no. 4, pp. 250–255, 2004.
[203] MRC (Ongoing), “Melatonin as a Novel Neuroprotectant
in Preterm,” http://england.ukcrn.org.uk/StudyDetail.aspx?
StudyID=8659.
[204] C. Zhu, W. Kang, F. Xu et al., “Erythropoietin improved
neurologic outcomes in newborns with hypoxic-ischemic
encephalopathy,” Pediatrics, vol. 124, no. 2, pp. e218–e226,
2009.